Fundraising Fox

Combined Therapeutics

Cambridge, US · Founded 2016 · Delaware corporation

Find your way into Combined Therapeutics

183 people in our graph share verified history with the Combined Therapeutics team — schools, employers, funds. One of them is your warm intro.

Scott Billerunlockedknows Dan Anderson · together at Foghorn Therapeutics Inc. (overlapped)
×2knows the team · via Northeastern University
×7knows the team · via United States Marine Corps
×2knows the team · via Trinity High School

Combined Therapeutics Inc. (CTx) is a privately held biotechnology company developing mRNA vaccines and therapeutics using a proprietary multi-organ protection technology for tissue-specific mRNA expression. Its initial focus is on vaccines and vaccine adjuvants for infectious diseases and oncology.

AI & Machine LearningBiotechHealthtech

Founders & leadership

Combined Therapeutics was founded in 2016 by Dan Anderson.

DADan Anderson
Dan AndersoninCo-founderCo-founder of Combined Therapeutics, a biotechnology company developing mRNA vaccines and therapeutics. Anderson has held operations roles with increasing responsibility across multiple organizations.
JR
Justine RyanNamed on SEC filing
RM
Romain MicolinPresident and co-founder CEO
PMPierre Matussiere
Pierre MatussiereinNon Executive Director
RL
Robert LangerCo-founder

Reported raises · per SEC filings

Form D private placements

$250K disclosed across 1 round · 2017

▶$250KraisedDec 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel AndersonDirector
  • Justine RyanDirector
  • Romain MicolExecutive Officer, Director
  • Pierre MatussiereDirector
  • Robert LangerDirector
Offering amount
$2M
Amount sold
$250K
First sale
Nov 2017
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Solu15 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Transcode Therapeutics14 shared keywordsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Bioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Combined Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Combined Therapeutics do?
Combined Therapeutics Inc. (CTx) is a privately held biotechnology company developing mRNA vaccines and therapeutics using a proprietary multi-organ protection technology for tissue-specific mRNA expression. Its initial focus is on vaccines and vaccine adjuvants for infectious diseases and oncology.
Who founded Combined Therapeutics?
Combined Therapeutics was founded by Dan Anderson in 2016.
How much funding has Combined Therapeutics raised?
Combined Therapeutics has disclosed $250K raised across 1 round.
Where is Combined Therapeutics headquartered?
Combined Therapeutics is headquartered in Cambridge, US.